Výsledky vyhledávání - "Hiroshi Kunikane"

Prospective analysis of the association between skeletal-related events and quality of life in patients with advanced lung cancer (CSP-HOR13)

Autor: Nobuyuki Katakami, Koichi Takayama, Soichiro Yokota, Yasuo Ohashi, Kenji Eguchi, Masao Harada, Hiroshi Saito, Hiroshi Kunikane, Toshiyuki Sawa, Kiyoshi Ando, Isao Yokota, Koji Takeda, Yuko Saito

A prospective study has previously reported on the incidence of bone metastasis (BM) and skeletal-related events (SREs) in patients with advanced lung cancer. The aim of the present study was to prospectively investigate how the quality of life (QOL)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b0362ba2ac027393cef5dda22239acf
https://europepmc.org/articles/PMC6312953/

Zobrazit plný text záznamu

A Phase II Study of Cisplatin and Irinotecan as Induction Chemotherapy Followed by Accelerated Hyperfractionated Thoracic Radiotherapy with Daily Low-dose Carboplatin in Unresectable Stage III Non-small Cell Lung Cancer: JCOG 9510

Autor: Nagahiro Saijo, Hideo Kunitoh, Kiyoshi Mori, Koshiro Watanabe, Tomoki Fujii, Hiroaki Okamoto, Haruhiko Fukuda, Tomohide Tamura, Akira Yokoyama, Hiroshi Kunikane

Publikováno v: Japanese Journal of Clinical Oncology. 39:784-790

Objective It is important to find optimal regimens of cisplatin (CDDP)-based third-generation chemotherapy and radiotherapy for patients with unresectable Stage III non-small cell lung cancer (NSCLC). Methods This Phase II study was designed to deter

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31a2f04a582a1ab335d52f56185012d6
https://doi.org/10.1093/jjco/hyp102

Zobrazit plný text záznamu

Dose-escalating and Pharmacokinetic Study of a Weekly Combination of Paclitaxel and Carboplatin for Inoperable Non-small Cell Lung Cancer: JCOG 9910-DI

Autor: Tomoki Fujii, Shuko Tsujimura, Koshiro Watanabe, Hiroaki Okamoto, Naoya Hida, Hiroshi Kunikane, Katsuhiko Naoki

Publikováno v: Japanese Journal of Clinical Oncology. 39:569-575

Objective: Combined paclitaxel and carboplatin is a standard regimen for inoperable nonsmall cell lung cancer (NSCLC). Although an every-3-week schedule is common, weekly paclitaxel is clinically effective for various cancers. A Phase I clinical tria

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0be183b57cce248cd5d7c5026c8c7e3
https://doi.org/10.1093/jjco/hyp059

Zobrazit plný text záznamu

Phase I/II Pharmacokinetic and Pharmacogenomic Study of UGT1A1 Polymorphism in Elderly Patients With Advanced Non–Small Cell Lung Cancer Treated With Irinotecan

Autor: T Takahashi, A Yokoyama, N. Yamamoto, Yuichiro Takeda, Kenji Eguchi, Takashi Ogura, Koshiro Watanabe, Hiroshi Isobe, Noriyuki Masuda, Hiroshi Kunikane, M Shibuya

Publikováno v: Clinical Pharmacology & Therapeutics. 85:149-154

This phase II study investigated the recommended dose (RD) of irinotecan (CPT-11) by dose escalation in elderly (≥70 years) chemotherapy-naive Japanese patients with advanced non–small cell lung cancer. UGT1A1*28 and *6 polymorphisms and pharmaco

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41e513dffa935e61712d82fe9787a93c
https://doi.org/10.1038/clpt.2008.152

Zobrazit plný text záznamu

Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702

Autor: Tomohide Tamura, Hiroaki Okamoto, K Watanabe, A Yokoyama, Nagahiro Saijo, Tatsuhiro Shibata, Hideo Kunitoh, T Asakawa, Hiroshi Kunikane, S. Kudoh

Publikováno v: British Journal of Cancer

We compared the efficacy and the safety of a carboplatin plus etoposide regimen (CE) vs split doses of cisplatin plus etoposide (SPE) in elderly or poor-risk patients with extensive disease small-cell lung cancer (ED-SCLC). Eligibility criteria inclu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d881c8bf7daa33480e918bb9865b44fc
http://europepmc.org/articles/PMC2360311

Zobrazit plný text záznamu

Phase II Trial of Amrubicin for Treatment of Refractory or Relapsed Small-Cell Lung Cancer: Thoracic Oncology Research Group Study 0301

Autor: Sayaka Onoda, Takayuki Kuriyama, Akira Yokoyama, Akihiro Tagawa, Noriyuki Masuda, Koshiro Watanabe, Masao Harada, Hiroaki Okamoto, Takashi Ogura, Nobuhiko Seki, Yoshiko Asaka-Amano, Kazutsugu Uematsu, Kenji Eguchi, Hiroshi Kunikane, Hiroshi Isobe, Yumi Kuroiwa, Takashi Seto, Masanori Yokoba, Yuichi Takiguchi

Publikováno v: Journal of Clinical Oncology. 24:5448-5453

Purpose This multicenter, phase II study was conducted to evaluate the activity of amrubicin, a topoisomerase II inhibitor, against refractory or relapsed small-cell lung cancer (SCLC). Patients and Methods SCLC patients with measurable disease who h

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62dc31d12022af5fd4d2468a5bbf2a7c
https://doi.org/10.1200/jco.2006.08.4145

Zobrazit plný text záznamu

A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer

Autor: Katsuhiko Naoki, Naoya Hida, Hiroshi Kunikane, Hiroaki Okamoto, Koshiro Watanabe, Yusuke Narita

Publikováno v: Lung Cancer. 53:197-203

Summary Background We have previously reported that carboplatin plus etoposide is an effective and relatively non-toxic regimen in elderly patients with small cell lung cancer (SCLC). Recently, the Japan Clinical Oncology Group reported that irinotec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8921707088dad5443ff7eff2c562e1c0
https://doi.org/10.1016/j.lungcan.2006.05.004

Zobrazit plný text záznamu

Response to Combined Modality Treatment in a Five-year Survivor of Extensive Small Cell Lung Cancer with Severe Complications

Autor: Hiroaki Okamoto, Koshiro Watanabe, Hiroshi Kunikane, Kanoko Sawafuji, Nobuo Nakamura, Akira Nagatomo

Publikováno v: Internal Medicine. 39:478-481

We present a rare case of a five-year survivor of small cell lung cancer with severe complications who responded to combined modality treatment. Prior to initial chemotherapy, he experienced severe complications including sepsis, pneumonia, ileus, an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2916f2439d93033f01fa2f32a985c717
https://doi.org/10.2169/internalmedicine.39.478

Zobrazit plný text záznamu

Phorbol ester-induced P-glycoprotein phosphorylation and functionality in the HTB-123 human breast cancer cell line

Autor: Cheppail Ramachandran, Wei You, Hiroshi Kunikane, Awtar Krishan

Publikováno v: Biochemical Pharmacology. 56:709-718

The discordance between P-glycoprotein (P-gp) expression and functionality [as measured by the efflux of doxorubicin (DOX)] was analyzed in a DOX-sensitive human breast cancer cell line (HTB-123) with high reactivity against four P-gp specific monocl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5176bd63d4acc5861aef3637d83b9055
https://doi.org/10.1016/s0006-2952(98)00215-9

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání